{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T04:04:53Z","timestamp":1775016293796,"version":"3.50.1"},"publisher-location":"Cham","reference-count":51,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319997155","type":"print"},{"value":"9783319997162","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,12,31]],"date-time":"2018-12-31T00:00:00Z","timestamp":1546214400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/978-3-319-99716-2_6","type":"book-chapter","created":{"date-parts":[[2018,12,30]],"date-time":"2018-12-30T16:33:57Z","timestamp":1546187637000},"page":"127-144","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management"],"prefix":"10.1007","author":[{"given":"Andrei","family":"Shustov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorinda","family":"Soma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,31]]},"reference":[{"issue":"25","key":"6_CR1","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Armitage","year":"2008","unstructured":"Armitage J, Vose J, Weisenburger D (2008) International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26(25):4124\u20134130. https:\/\/doi.org\/10.1200\/JCO.2008.16.4558","journal-title":"J Clin Oncol"},{"issue":"1","key":"6_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","volume":"107","author":"LM Morton","year":"2006","unstructured":"Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS (2006) Lymphoma incidence patterns by WHO subtype in the united states, 1992\u20132001. Blood 107(1):265\u2013276","journal-title":"Blood"},{"key":"6_CR3","doi-asserted-by":"crossref","unstructured":"Adams SV, Newcomb PA, Shustov AR (2016) Racial patterns of peripheral T-cell lymphoma incidence and survival in the united states. J Clin Oncol","DOI":"10.1200\/JCO.2015.63.5540"},{"issue":"12","key":"6_CR4","doi-asserted-by":"publisher","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","volume":"111","author":"KJ Savage","year":"2008","unstructured":"Savage KJ, Harris NL, Vose JM et al (2008) ALK\u2212 anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+\u2009ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the international peripheral T-cell lymphoma project. Blood 111(12):5496\u20135504","journal-title":"Blood"},{"issue":"2","key":"6_CR5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1200\/JCO.2013.52.7911","volume":"32","author":"RN Miranda","year":"2014","unstructured":"Miranda RN, Aladily TN, Prince HM et al (2014) Breast implant-associated anaplastic large-cell lymphoma: Long-term follow-up of 60 patients. J Clin Oncol 32(2):114\u2013120. https:\/\/doi.org\/10.1200\/JCO.2013.52.7911","journal-title":"J Clin Oncol"},{"key":"6_CR6","unstructured":"Swerdlow SH, Campo E, Harris NL et al (2017) WHO classification of tumours of haematopoietic and lymphoid tissues"},{"issue":"1","key":"6_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/PAS.0000000000000500","volume":"40","author":"RL King","year":"2016","unstructured":"King RL, Dao LN, McPhail ED et al (2016) Morphologic features of ALK-negative anaplastic large cell lymphomas with DUSP22 rearrangements. Am J Surg Pathol 40(1):36\u201343. https:\/\/doi.org\/10.1097\/PAS.0000000000000500","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"6_CR8","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1093\/annonc\/mdv575","volume":"27","author":"C Laurent","year":"2016","unstructured":"Laurent C, Delas A, Gaulard P et al (2016) Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes. Ann Oncol 27(2):306\u2013314. https:\/\/doi.org\/10.1093\/annonc\/mdv575","journal-title":"Ann Oncol"},{"issue":"9","key":"6_CR9","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.3324\/haematol.2014.107938","volume":"99","author":"KA Ganapathi","year":"2014","unstructured":"Ganapathi KA, Pittaluga S, Odejide OO, Freedman AS, Jaffe ES (2014) Early lymphoid lesions: conceptual, diagnostic and clinical challenges. Haematologica 99(9):1421\u20131432. https:\/\/doi.org\/10.3324\/haematol.2014.107938","journal-title":"Haematologica"},{"issue":"5","key":"6_CR10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1309\/R2Q9CCUVTLRYCF3H","volume":"127","author":"LJ Medeiros","year":"2007","unstructured":"Medeiros LJ, Elenitoba-Johnson KS (2007) Anaplastic large cell lymphoma. Am J Clin Pathol 127(5):707\u2013722","journal-title":"Am J Clin Pathol"},{"issue":"32","key":"6_CR11","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1200\/JCO.2012.42.2345","volume":"30","author":"D Sibon","year":"2012","unstructured":"Sibon D, Fournier M, Briere J et al (2012) Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the groupe d\u2019etude des lymphomes de l\u2019adulte trials. J Clin Oncol 30(32):3939\u20133946. https:\/\/doi.org\/10.1200\/JCO.2012.42.2345","journal-title":"J Clin Oncol"},{"issue":"18","key":"6_CR12","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz N, Trumper L, Ziepert M et al (2010) Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the german high-grade non-hodgkin lymphoma study group. Blood 116(18):3418\u20133425","journal-title":"Blood"},{"issue":"1","key":"6_CR13","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.3324\/haematol.2015.131151","volume":"101","author":"K Dunleavy","year":"2016","unstructured":"Dunleavy K, Pittaluga S, Shovlin M et al (2016) Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma. Haematologica 101(1):e27\u20139. https:\/\/doi.org\/10.3324\/haematol.2015.131151","journal-title":"Haematologica"},{"issue":"9","key":"6_CR14","first-page":"2993","volume":"96","author":"R Suzuki","year":"2000","unstructured":"Suzuki R, Kagami Y, Takeuchi K et al (2000) Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T\/null cell phenotype. Blood 96(9):2993\u20133000","journal-title":"Blood"},{"issue":"40","key":"6_CR15","doi-asserted-by":"publisher","first-page":"5623","DOI":"10.1038\/sj.onc.1204594","volume":"20","author":"J Duyster","year":"2001","unstructured":"Duyster J, Bai RY, Morris SW (2001) Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 20(40):5623\u20135637. https:\/\/doi.org\/10.1038\/sj.onc.1204594","journal-title":"Oncogene"},{"issue":"3","key":"6_CR16","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1182\/blood-2013-09-526202","volume":"123","author":"C Damm-Welk","year":"2014","unstructured":"Damm-Welk C, Mussolin L, Zimmermann M et al (2014) Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma. Blood 123(3):334\u2013337","journal-title":"Blood"},{"issue":"10","key":"6_CR17","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","volume":"15","author":"KJ Savage","year":"2004","unstructured":"Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM (2004) Characterization of peripheral T-cell lymphomas in a single north american institution by the WHO classification. Ann Oncol 15(10):1467\u20131475","journal-title":"Ann Oncol"},{"issue":"9","key":"6_CR18","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","volume":"124","author":"ER Parrilla Castellar","year":"2014","unstructured":"Parrilla Castellar ER, Jaffe ES, Said JW et al (2014) ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 124(9):1473\u20131480. https:\/\/doi.org\/10.1182\/blood-2014-04-571091","journal-title":"Blood"},{"issue":"24","key":"6_CR19","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1200\/JCO.2012.42.5611","volume":"31","author":"PP Piccaluga","year":"2013","unstructured":"Piccaluga PP, Fuligni F, De Leo A et al (2013) Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study. J Clin Oncol 31(24):3019\u20133025. https:\/\/doi.org\/10.1200\/JCO.2012.42.5611","journal-title":"J Clin Oncol"},{"issue":"10","key":"6_CR20","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","volume":"124","author":"F Ellin","year":"2014","unstructured":"Ellin F, Landstrom J, Jerkeman M, Relander T (2014) Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the swedish lymphoma registry. Blood 124(10):1570\u20131577. https:\/\/doi.org\/10.1182\/blood-2014-04-573089","journal-title":"Blood"},{"issue":"12","key":"6_CR21","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1200\/JCO.1999.17.12.3776","volume":"17","author":"CH Moskowitz","year":"1999","unstructured":"Moskowitz CH, Bertino JR, Glassman JR et al (1999) Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-hodgkin\u2019s lymphoma. J Clin Oncol 17(12):3776\u20133785. https:\/\/doi.org\/10.1200\/JCO.1999.17.12.3776","journal-title":"J Clin Oncol"},{"issue":"3","key":"6_CR22","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1200\/JCO.1991.9.3.423","volume":"9","author":"OW Press","year":"1991","unstructured":"Press OW, Livingston R, Mortimer J, Collins C, Appelbaum F (1991) Treatment of relapsed non-hodgkin\u2019s lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation. J Clin Oncol 9(3):423\u2013431. https:\/\/doi.org\/10.1200\/JCO.1991.9.3.423","journal-title":"J Clin Oncol"},{"issue":"6","key":"6_CR23","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.3109\/10428194.2012.739286","volume":"54","author":"YY Yao","year":"2013","unstructured":"Yao YY, Tang Y, Zhu Q et al (2013) Gemcitabine, oxaliplatin and dexamethasone as salvage treatment for elderly patients with refractory and relapsed peripheral T-cell lymphoma. Leuk Lymphoma 54(6):1194\u20131200. https:\/\/doi.org\/10.3109\/10428194.2012.739286","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"6_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3816\/CLM.2004.n.009","volume":"5","author":"Christos Emmanouilides","year":"2004","unstructured":"Emmanouilides C, Colovos C, Pinter-Brown L et al (2004) Pilot study of fixed-infusion rate gemcitabine with cisplatin and dexamethasone in patients with relapsed or refractory lymphoma. Clin Lymphoma 5(1):45\u201349. S1526-9655(11)70055-0 [pii]","journal-title":"Clinical Lymphoma"},{"issue":"2","key":"6_CR25","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.hoc.2016.11.003","volume":"31","author":"Tejaswini M. Dhawale","year":"2017","unstructured":"Dhawale TM, Shustov AR (2017) Autologous and allogeneic hematopoietic cell transplantation in peripheral T\/NK-cell lymphomas: a histology-specific review. Hematol Oncol Clin North Am 31(2):335\u2013357. S0889-8588(16)30171-X [pii]","journal-title":"Hematology\/Oncology Clinics of North America"},{"issue":"5","key":"6_CR26","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/sj.bmt.1701596","volume":"23","author":"R Fanin","year":"1999","unstructured":"Fanin R, Ruiz de Elvira MC, Sperotto A, Baccarani M, Goldstone A (1999) Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the european group for blood and marrow transplantation (EBMT). Bone Marrow Transp 23(5):437\u2013442","journal-title":"Bone Marrow Transp"},{"issue":"25","key":"6_CR27","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","volume":"31","author":"SM Smith","year":"2013","unstructured":"Smith SM, Burns LJ, van Besien K et al (2013) Hematopoietic cell transplantation for systemic mature T-cell non-hodgkin lymphoma. J Clin Oncol 31(25):3100\u20133109. https:\/\/doi.org\/10.1200\/JCO.2012.46.0188","journal-title":"J Clin Oncol"},{"issue":"14","key":"6_CR28","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","volume":"26","author":"S Gouill Le","year":"2008","unstructured":"Le Gouill S, Milpied N, Buzyn A et al (2008) Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the societe francaise de greffe de moelle et de therapie cellulaire. J Clin Oncol 26(14):2264\u20132271","journal-title":"J Clin Oncol"},{"issue":"2","key":"6_CR29","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-2141.2010.08210.x","volume":"150","author":"AR Shustov","year":"2010","unstructured":"Shustov AR, Gooley TA, Sandmaier BM et al (2010) Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas. Br J Haematol 150(2):170\u2013178","journal-title":"Br J Haematol"},{"issue":"15","key":"6_CR30","doi-asserted-by":"publisher","first-page":"10540","DOI":"10.1074\/jbc.M510026200","volume":"281","author":"May S. Kung Sutherland","year":"2006","unstructured":"Sutherland MS, Sanderson RJ, Gordon KA et al (2006) Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem 281(15):10540\u201310547. M510026200 [pii]","journal-title":"Journal of Biological Chemistry"},{"issue":"18","key":"6_CR31","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","volume":"30","author":"B Pro","year":"2012","unstructured":"Pro B, Advani R, Brice P et al (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 30(18):2190\u20132196","journal-title":"J Clin Oncol"},{"issue":"25","key":"6_CR32","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","volume":"130","author":"B Pro","year":"2017","unstructured":"Pro B, Advani R, Brice P et al (2017) Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood 130(25):2709\u20132717. https:\/\/doi.org\/10.1182\/blood-2017-05-780049","journal-title":"Blood"},{"issue":"28","key":"6_CR33","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1200\/JCO.2013.54.2456","volume":"32","author":"MA Fanale","year":"2014","unstructured":"Fanale MA, Horwitz SM, Forero-Torres A et al (2014) Brentuximab vedotin in the front-line treatment of patients with CD30+\u2009peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol 32(28):3137\u20133143","journal-title":"J Clin Oncol"},{"issue":"19","key":"6_CR34","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1182\/blood-2017-12-821009","volume":"131","author":"MA Fanale","year":"2018","unstructured":"Fanale MA, Horwitz SM, Forero-Torres A et al (2018) Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas. Blood 131(19):2120\u20132124. https:\/\/doi.org\/10.1182\/blood-2017-12-821009","journal-title":"Blood"},{"issue":"6","key":"6_CR35","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","volume":"14","author":"YP Mosse","year":"2013","unstructured":"Mosse YP, Lim MS, Voss SD et al (2013) Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a children\u2019s oncology group phase 1 consortium study. Lancet Oncol 14(6):472\u2013480","journal-title":"Lancet Oncol"},{"issue":"2","key":"6_CR36","first-page":"218","volume":"26","author":"C Kyriakou","year":"2008","unstructured":"Kyriakou C, Canals C, Goldstone A et al (2008) High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of outcome-lymphoma working party of the european group for blood and marrow transplantation. J Clin Oncol 26(2):218\u2013224","journal-title":"J Clin Oncol"},{"issue":"4","key":"6_CR37","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/bjh.13628","volume":"171","author":"D Chihara","year":"2015","unstructured":"Chihara D, Pro B, Loghavi S et al (2015) Phase II study of HCVIDD\/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol 171(4):509\u2013516. https:\/\/doi.org\/10.1111\/bjh.13628","journal-title":"Br J Haematol"},{"issue":"4","key":"6_CR38","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s11899-009-0031-4","volume":"4","author":"F d\u2019Amore","year":"2009","unstructured":"d\u2019Amore F, Jantunen E, Relander T (2009) Hemopoietic stem cell transplantation in T-cell malignancies: who, when, and how? Curr Hematol Malig Rep 4(4):236\u2013244","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"6_CR39","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","volume":"27","author":"P Reimer","year":"2009","unstructured":"Reimer P, Rudiger T, Geissinger E et al (2009) Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 27(1):106\u2013113","journal-title":"J Clin Oncol"},{"issue":"25","key":"6_CR40","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","volume":"30","author":"F d\u2019Amore","year":"2012","unstructured":"d\u2019Amore F, Relander T, Lauritzsen GF et al (2012) Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 30(25):3093\u20133099","journal-title":"J Clin Oncol"},{"issue":"19","key":"6_CR41","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","volume":"123","author":"J Iqbal","year":"2014","unstructured":"Iqbal J, Wright G, Wang C et al (2014) Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 123(19):2915\u20132923","journal-title":"Blood"},{"issue":"4","key":"6_CR42","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s002800050823","volume":"42","author":"FM Sirotnak","year":"1998","unstructured":"Sirotnak FM, DeGraw JI, Colwell WT, Piper JR (1998) A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Cancer Chemother Pharmacol 42(4):313\u2013318","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"6_CR43","first-page":"26","volume":"12","author":"FM Sirotnak","year":"1984","unstructured":"Sirotnak FM, DeGraw JI, Schmid FA, Goutas LJ, Moccio DM (1984) New folate analogs of the 10-deaza-aminopterin series. further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models. Cancer Chemother Pharmacol 12(1):26\u201330","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"6_CR44","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","volume":"29","author":"OA O\u2019Connor","year":"2011","unstructured":"O\u2019Connor OA, Pro B, Pinter-Brown L et al (2011) Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 29(9):1182\u20131189","journal-title":"J Clin Oncol"},{"issue":"6","key":"6_CR45","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier B, Pro B, Prince HM et al (2012) Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 30(6):631\u2013636","journal-title":"J Clin Oncol"},{"issue":"23","key":"6_CR46","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","volume":"33","author":"OA O\u2019Connor","year":"2015","unstructured":"O\u2019Connor OA, Horwitz S, Masszi T et al (2015) Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol 33(23):2492\u20132499. https:\/\/doi.org\/10.1200\/JCO.2014.59.2782","journal-title":"J Clin Oncol"},{"key":"6_CR47","unstructured":"Strati P, Chihara D, Oki Y et al (2018) A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Haematologica. haematol.2018.187617 [pii]"},{"issue":"1","key":"6_CR48","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1182\/blood-2014-12-616961","volume":"126","author":"F Ellin","year":"2015","unstructured":"Ellin F, Landstrom J, Jerkeman M, Relander T (2015) Central nervous system relapse in peripheral T-cell lymphomas: a Swedish lymphoma registry study. Blood 126(1):36\u201341. https:\/\/doi.org\/10.1182\/blood-2014-12-616961","journal-title":"Blood"},{"issue":"5","key":"6_CR49","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3109\/0284186X.2015.1118656","volume":"55","author":"R Gurion","year":"2016","unstructured":"Gurion R, Mehta N, Migliacci JC et al (2016) Central nervous system involvement in T-cell lymphoma: a single center experience. Acta Oncol 55(5):561\u2013566. https:\/\/doi.org\/10.3109\/0284186X.2015.1118656","journal-title":"Acta Oncol"},{"issue":"12","key":"6_CR50","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/nm.4444","volume":"23","author":"PM Maciocia","year":"2017","unstructured":"Maciocia PM, Wawrzyniecka PA, Philip B et al (2017) Targeting the T cell receptor beta-chain constant region for immunotherapy of T cell malignancies. Nat Med 23(12):1416\u20131423. https:\/\/doi.org\/10.1038\/nm.4444","journal-title":"Nat Med"},{"issue":"2","key":"6_CR51","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1200\/JCO.2015.63.3412","volume":"34","author":"MW Clemens","year":"2016","unstructured":"Clemens MW, Medeiros LJ, Butler CE et al (2016) Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma. J Clin Oncol 34(2):160\u2013168. https:\/\/doi.org\/10.1200\/JCO.2015.63.3412","journal-title":"J Clin Oncol"}],"container-title":["Cancer Treatment and Research","T-Cell and NK-Cell Lymphomas"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-99716-2_6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T18:24:37Z","timestamp":1720895077000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-319-99716-2_6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,31]]},"ISBN":["9783319997155","9783319997162"],"references-count":51,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-99716-2_6","relation":{},"ISSN":["0927-3042","2509-8497"],"issn-type":[{"value":"0927-3042","type":"print"},{"value":"2509-8497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,31]]}}}